228 related articles for article (PubMed ID: 21148085)
1. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
[TBL] [Abstract][Full Text] [Related]
2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
3. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
Harris NC; Davydova N; Roufail S; Paquet-Fifield S; Paavonen K; Karnezis T; Zhang YF; Sato T; Rothacker J; Nice EC; Stacker SA; Achen MG
J Biol Chem; 2013 Mar; 288(12):8176-8186. PubMed ID: 23404505
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
7. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.
Leppänen VM; Tvorogov D; Kisko K; Prota AE; Jeltsch M; Anisimov A; Markovic-Mueller S; Stuttfeld E; Goldie KN; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12960-5. PubMed ID: 23878260
[TBL] [Abstract][Full Text] [Related]
8. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
9. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.
McColl BK; Paavonen K; Karnezis T; Harris NC; Davydova N; Rothacker J; Nice EC; Harder KW; Roufail S; Hibbs ML; Rogers PA; Alitalo K; Stacker SA; Achen MG
FASEB J; 2007 Apr; 21(4):1088-98. PubMed ID: 17242158
[TBL] [Abstract][Full Text] [Related]
11. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
Chung ES; Chauhan SK; Jin Y; Nakao S; Hafezi-Moghadam A; van Rooijen N; Zhang Q; Chen L; Dana R
Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
[TBL] [Abstract][Full Text] [Related]
12. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
13. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
[TBL] [Abstract][Full Text] [Related]
14. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
15. Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal muscle.
Kivelä R; Silvennoinen M; Lehti M; Kainulainen H; Vihko V
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2573-9. PubMed ID: 17766486
[TBL] [Abstract][Full Text] [Related]
16. Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.
Blacker HA; Orgeig S
J Comp Physiol B; 2012 Jan; 182(1):109-26. PubMed ID: 21800152
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
19. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2.
Kirkin V; Mazitschek R; Krishnan J; Steffen A; Waltenberger J; Pepper MS; Giannis A; Sleeman JP
Eur J Biochem; 2001 Nov; 268(21):5530-40. PubMed ID: 11683876
[TBL] [Abstract][Full Text] [Related]
20. The comparison of VEGFR-1-binding domain of VEGF-A with modelled VEGF-C sheds light on receptor specificity.
Kasap M; Sazci A
J Theor Biol; 2008 Aug; 253(3):446-51. PubMed ID: 18479712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
